Payment overview · 2025
General Payments
$167.36
8 reported records · 5 companies
Healthcare provider profile · identity verified
Breana Strong
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · NOVI, MI · NPI 1184206658
Verified facts
What the public records show
CMS Open Payments records show Breana Strong received $167.36 in general payments during 2025 across 8 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 54.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $90.70 | 54.2% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $24.03 | 14.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.70 | 13.0% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.42 | 9.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.51 | 8.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $167.36 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $90.70 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Quetiapine Fumarate | Quetiapine Fumarate | 351 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 346 | 45 |
| Atorvastatin Calcium | Atorvastatin Calcium | 333 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 329 | 44 |
| Omeprazole | Omeprazole | 286 | 40 |
| Sertraline Hcl | Sertraline Hcl | 262 | 43 |
| Losartan Potassium | Losartan Potassium | 252 | 32 |
| Potassium Chloride | Potassium Chloride | 225 | 39 |
| Donepezil Hcl | Donepezil Hcl | 194 | 33 |
| Furosemide | Furosemide | 188 | 34 |
| Eliquis | Apixaban | 185 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 183 | 26 |
| Memantine Hcl | Memantine Hcl | 159 | 27 |
| Gabapentin | Gabapentin | 139 | 23 |
| Mirtazapine | Mirtazapine | 137 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 27 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 108 | 78 |
| Montelukast Sodium | Montelukast Sodium | 99 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 98 | 17 |
| Trazodone Hcl | Trazodone Hcl | 97 | 14 |
| Lisinopril | Lisinopril | 88 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | suppressed |
| Simvastatin | Simvastatin | 84 | 12 |
| Celecoxib | Celecoxib | 79 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 76 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 73 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 70 | 15 |
| Latanoprost | Latanoprost | 69 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | suppressed |
| Famotidine | Famotidine | 63 | suppressed |
| Metformin Hcl | Metformin Hcl | 61 | 12 |
| Methocarbamol | Methocarbamol | 61 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 14 |
| Allopurinol | Allopurinol | 58 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 11 |
| Cephalexin | Cephalexin | 54 | 31 |
| Divalproex Sodium | Divalproex Sodium | 53 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 51 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 51 | 15 |
| Carvedilol | Carvedilol | 50 | suppressed |
| Alprazolam | Alprazolam | 49 | 16 |
| Pregabalin | Pregabalin | 46 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 43 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 42 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | suppressed |
| Risperidone | Risperidone | 41 | suppressed |
| Bumetanide | Bumetanide | 37 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 37 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Ezetimibe | Ezetimibe | 35 | suppressed |
| Primidone | Primidone | 35 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 32 | suppressed |
| Lorazepam | Lorazepam | 31 | 14 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 29 | suppressed |
| Olanzapine | Olanzapine | 29 | suppressed |
| Torsemide | Torsemide | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | 13 |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 17 |
| Loperamide | Loperamide Hcl | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 12 |
| Methylprednisolone | Methylprednisolone | 20 | 12 |
| Brimonidine Tartrate | Brimonidine Tartrate | 19 | suppressed |
| Haloperidol | Haloperidol | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Teriflunomide | Teriflunomide | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Budesonide Ec | Budesonide | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $167.36 · 8 records | Otsuka America Pharmaceutical, Inc. | BREZTRI, CREXONT, KISUNLA, Korlym, REXULTI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error